2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1940

Investigating the Post-Partum Flare in Rheumatoid Arthritis Using Transcriptome Analysis
Abstract Number: 2714

Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry
Abstract Number: 770

Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
Abstract Number: 2033

IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells
Abstract Number: 647

Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?
Abstract Number: 1441

Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Abstract Number: 2334

Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?
Abstract Number: 781

Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?
Abstract Number: 1752

Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?
Abstract Number: 1255

Is Exon 2 Associated with FMF or a New Disease?
Abstract Number: 229

Is Fibromyalgia Associated with Structural or Functional Abnormalities in Skeletal Muscle?
Abstract Number: 909

Is Long-term High-intensity Strength Training Beneficial or Harmful for Knee Osteoarthritis Patients? The Strength Training and Arthritis Trial (START)
Abstract Number: 292

Is Shoulder Involvement an Early Feature of Rheumatoid Arthritis in Clinically Suspect Arthralgia? A Longitudinal Ultrasound Study
Abstract Number: 172

Is the Epidemiology of Rheumatoid Arthritis (RA) Changing? Results from a Population-based Incidence Cohort of RA Patients, 2005-2014
Abstract Number: 795

Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].